Vector Science and Therapeutics Corp. (TSXV:PAIN) shares fell on Wednesday, November 18, closing at $2.69, down 38 cents, on the same day the peptide company announced a research collaboration with the foundation of famed sports surgeon Dr. James Andrews.
The stock had climbed steeply in the weeks before the long-flagged announcement, and the decline looks like traders locking in gains once the news landed, on a day when the wider market sold off hard.
What happened
Before the market opened on Wednesday, Vector and the Andrews Research & Education Foundation said they would design and start clinical programs to evaluate Vector's pharma-grade peptides for musculoskeletal uses.
The named areas are soft-tissue repair after activity or injury, muscle regeneration in aging athletes and degenerative osteoarthritis. The foundation brings research and clinical expertise from its Gulf Breeze, Florida facility, while Vector will formulate, Supply and test the peptides at its Mequon, Wisconsin site. Jointly owned intellectual property will cover new findings, and Vector will lead commercialization.
The release did not disclose financial terms, specific peptides, trial designs or timelines. A livestreamed media briefing from Gulf Breeze was scheduled for later that morning, with Dr. Andrews, Vector chairman Tommy Thompson and other physicians listed as speakers.
“The use of peptides in medical practice is innovation that requires attention now,” Dr. Andrews said in the release.
"The relationship with AREF represents a pivotal moment for Vector and the medical community," chief executive Bill Jackson said.
About 68,500 shares traded.
Why it matters
The decline needs to be read against how far the stock had already run. Vector closed at $2.03 on November 3. Based on Wednesday's move, it finished Tuesday at about $3.07, meaning the shares had risen by roughly half in about two weeks.
The deal had also been flagged in advance, with Vector promoting an upcoming announcement by Dr. Andrews and Mr. Thompson, a former U.S. secretary of health and human services. When good news is widely expected, some traders sell once it arrives.
The collaboration itself is early-stage, and the release gave no indication of when results might come.
The bigger picture
Small, momentum-driven stocks tend to suffer most when markets turn defensive. The S&P/TSX Composite fell 737.25 points to 34,578.05, its fifth straight loss, its lowest close since early June and its worst one-day drop in five months.
Vector has been busy this autumn. It has made Simple Agreement for Future Equity investments in Gary Payton's Scoreboard and Whoopi Goldberg-backed Whoopi Wellness to develop peptide products, introduced a microneedle delivery technology and named Capital Markets veteran Russell Starr as president.
Peptides have drawn growing attention in the U.S., where Vector has positioned itself as a regulated, quality-focused supplier. It works with Lyogenesis on Manufacturing under current good manufacturing practice standards, and says it holds 15 pending Patent applications covering peptide and biologic delivery methods.
What to watch next
The selling did not stop there. On Thursday the Composite lost another 549.32 points to 34,028.73, its sixth straight decline, and the S&P/TSX Venture Composite fell sharply to 716.09.
Investors will look for details on the first clinical programs with the Andrews foundation, including which peptides will be studied and when work begins. Updates from the Scoreboard and Whoopi Wellness partnerships, and any Revenue from Vector's manufacturing arrangements, could help show whether its growing list of deals is turning into sales.
Given the size of the recent rally, further swings in either direction would not be surprising.






Please wait processing your request...